COMMUNIQUÉS West-GlobeNewswire

Genmab Announces Financial Results for the Nine Months of 2026
05/11/2026
November 5, 2026 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2026 Highlights Epcoritamab approved in Europe (as TEPKINLY ® ) and Japan (as EPKINLY ® ) in combination with R² for the [...]
Osteal Therapeutics Announces Three Scientific Presentations Related to the APEX Clinical Trial Program at the 2026 AAHKS Annual Meeting
05/11/2026
Presentations will address 24-month treatment outcomes, systemic antibiotic exposure, and new treatment strategies for recalcitrant periprosthetic joint infection DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Osteal [...]
Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
05/11/2026
FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months FORT LEE [...]
Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL
05/11/2026
Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting ® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGY À la semaine 52, 85,3 % des patients recevant [...]
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
05/11/2026
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® [...]
RAMSAY SANTE : résultats intermédiaires au 30 septembre 2026
05/11/2026
COMMUNIQUÉ DE PRESSE Paris, 5 novembre 2026 Résultats trimestriels non audités à fin septembre 2026 Ramsay Santé affiche une solide performance au premier trimestre, avec une croissance continue de son chiffre d’ [...]
RAMSAY SANTE : Unaudited interim results at the end of September 2026
05/11/2026
PRESS RELEASE Paris, 5 th November 2026 Unaudited interim results at the end of September 2026 Ramsay Santé delivers solid first-quarter performance, with continued revenue growth and improved operational performance [...]
Significant growth in both revenue and earnings
05/11/2026
ANNOUNCEMENT NR. 325 5 November 2026 Trading statement for Q1 2026/27 (1 July – 30 September 2026) Significant growth in both revenue and earnings Revenue was up by 28% in Q1 2026/27 to DKK 160.0 million from DKK 124.6 [...]
GENFIT : Information financière du troisième trimestre 2026 et point sur les activités de la Société
05/11/2026
La trésorerie et les équivalents de trésorerie s’élèvent à 95,6 millions d’euros au 30 septembre 2026 et permettent un financement des activités au-delà de fin 2028. La croissance attendue des revenus futurs, combinée [...]
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
05/11/2026
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward [...]
Scipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in Colombia
05/11/2026
DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been [...]
Novastra Therapeutics Establishes Scientific Advisory Board and Appoints Senior Advisors and Head of Clinical Development
05/11/2026
Experts in immuno-oncology, medical oncology, clinical development, and regulatory affairs to guide and support advancement of OmniAntigen™ Platform (OAP) programs OAP enables systematic immune reprogramming therapy ( [...]
Ovid Therapeutics to Participate in Upcoming Investor Conferences
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today [...]
SpyGlass Pharma to Participate in Upcoming Investor Conferences
05/11/2026
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management [...]
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
05/11/2026
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Science 37 Named 2026 “BioTechnology Innovation of the Year” for its Direct-to-Patient Clinical Trial Delivery Model
05/11/2026
The BioTech Breakthrough Award recognizes Science 37’s Direct-to-Patient Site model for expanding patient access and delivering measurable clinical trial performance nationwide MORRISVILLE, N.C., Nov. 05, 2026 (GLOBE [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
05/11/2026
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment [...]

Pages